Abstract

Deciphering molecular mechanisms underlying division of hematopoietic stem cells (HSCs) and malignant precursors would improve our understanding of basis of stem cell-fate decisions and oncogenic transformation. Using a novel reporter of hematopoietic precursor Evi1-GFP, we track the division of hematopoietic precursors in culture in real time. First, we confirmed that Evi1-GFP is a faithful reporter of HSC activity and identified three dividing patterns of HSCs: symmetric renewal, symmetric differentiation, and asymmetric division. Moreover, we found that the cytokines and growth factors combination (STIF) promotes symmetric renewal, whereas OP9 stromal cells balance symmetric renewal and differentiation of HSCs ex vivo .Interestingly, we found that Tet2 knockout HSCs underwent more symmetric differentiation in culture compared to wild type control. Intriguingly, OP9 stromal cells reverse the phenotype of Tet2 knockout HSCs ex vivo . Furthermore, we demonstrated that Tet2-/- ; Flt3 ITD acute myeloid leukemia (AML) precursors primarily underwent symmetric renewal divisions in culture. Our study establishes a new system to explore the molecular mechanisms of the regulation of benign and malignant hematopoietic precursor division ex vivo . Theknowledge learned from these studies will provide new insights into the molecular mechanisms of HSC fate decision and leukemogenesis. Disclosures No relevant conflicts of interest to declare.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.